Sellas Life Sciences Group (ehemals Galena Biopharma) (Seite 87)
eröffnet am 30.10.12 22:43:19 von
neuester Beitrag 05.05.24 17:10:19 von
neuester Beitrag 05.05.24 17:10:19 von
Beiträge: 2.941
ID: 1.177.530
ID: 1.177.530
Aufrufe heute: 4
Gesamt: 345.893
Gesamt: 345.893
Aktive User: 0
ISIN: US81642T2096 · WKN: A2PU3T · Symbol: RXK3
1,2000
EUR
+1,01 %
+0,0120 EUR
Letzter Kurs 10:05:06 Tradegate
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5700 | +55,23 | |
| 5,4500 | +41,56 | |
| 1,0000 | +33,33 | |
| 119,40 | +29,92 | |
| 11,500 | +18,31 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,9235 | -16,88 | |
| 5,2500 | -19,23 | |
| 5,9000 | -22,37 | |
| 0,5485 | -29,68 | |
| 2,5600 | -70,32 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 52.443.219 von Itzi am 19.05.16 22:29:30Wirklich, bei unserem Baby, GALE, braucht man starke Nerven.
Ich bin hier sehr gespannt,bin immer noch mit einer kleinen Pos. investiert,warte aber ab
geht die Rakete habe ich weniger Gewinn ,aber schone meine Nerven !
geht die Rakete habe ich weniger Gewinn ,aber schone meine Nerven !
Antwort auf Beitrag Nr.: 52.442.355 von alfarr27 am 19.05.16 20:08:28Hoffentlich schliessen wir noch zu 1,48 $.
Gruss
Andy
Gruss
Andy
Antwort auf Beitrag Nr.: 52.442.220 von kusbas am 19.05.16 19:54:14Tja die Amis haben mal wieder Angst vor ner Zinserhöhung und da ist mal wieder Panik angesagt. Da wird heut mal wieder alles abverkauft, auch GALE.
Hoffentlich ist das Zinstheater bald mal vorbei...
Hoffentlich ist das Zinstheater bald mal vorbei...
Oh man, war doch nichts mit einer Explosion. Schade.
Trading Spotlight
Antwort auf Beitrag Nr.: 52.438.557 von Growth2012 am 19.05.16 12:18:10Hi Growth. War gestern auch auf der Seite. Wenn das alles eitreffen soll bzw. wird dann kann man ungefähr vorstellen wo der Kurs sein wird und zwar zweistellig.
Gruss
Andy
Gruss
Andy
Antwort auf Beitrag Nr.: 52.437.951 von Blackwater01 am 19.05.16 11:26:37Keine Ahnung ob alles stimmt, aber der folgende Threadüberschrift drüben auf Yahoo (im Bezug auf dem gestrigen Handelssitzung hat mir sehr gut gefallen vorhin
50%+ Huge Short Volume Today & Gale was up 12% Massively Bullish / Shorts trying to hold the PPS but There is No Escape/ Get 'Em Cheap Now
FBP Proved Very Durable in the Optimally Dosed group - a 200% Increase in Progression Free survival
- these are the results Fast Track Designation and early FDA approval Are made for - FBP very Valuable
- Galena Will put a full on Press Release to announce these two year results
- This data will be published in Poster Format at ASCO June 6
- Galena will also announce the VADIS Trial in collaboration with the NCI by the end of June
- Gale will also Officially settle all the pending litigation June 23rd
- Gale present AnagrelideCR data at ASH in June
and the biggest kahuna
- Neuvax Phase 3 PRESENT Data IDMC recommendation by the End of JUNE
This is a good time to get invested in GALE - Shorts have nowhere to go
...we will see
50%+ Huge Short Volume Today & Gale was up 12% Massively Bullish / Shorts trying to hold the PPS but There is No Escape/ Get 'Em Cheap Now
FBP Proved Very Durable in the Optimally Dosed group - a 200% Increase in Progression Free survival
- these are the results Fast Track Designation and early FDA approval Are made for - FBP very Valuable
- Galena Will put a full on Press Release to announce these two year results
- This data will be published in Poster Format at ASCO June 6
- Galena will also announce the VADIS Trial in collaboration with the NCI by the end of June
- Gale will also Officially settle all the pending litigation June 23rd
- Gale present AnagrelideCR data at ASH in June
and the biggest kahuna
- Neuvax Phase 3 PRESENT Data IDMC recommendation by the End of JUNE
This is a good time to get invested in GALE - Shorts have nowhere to go
...we will see
Antwort auf Beitrag Nr.: 52.437.741 von Growth2012 am 19.05.16 11:06:57
Danke....und gerne...bei der Seite hat man schnell alle relevanten Indikatoren auf einen Blick
Wenn es heute zu keinem Abverkauf im Handelsverlauf in USA kommt....bin ich seehr zuversichtlich das wir einer stabilen Trendwende entgegen sehen dürfen bei GALE.
Ich hoffe das die 2$ Marke bald.....gerissen werden wird !
Zitat von Growth2012: @Blackwater, klasse Seite (die Chartdarstellung gefällt mir außerordentlich gut), Danke fürs reinstellen-Wilkommen im Bord, und am Board
Danke....und gerne...bei der Seite hat man schnell alle relevanten Indikatoren auf einen Blick
Wenn es heute zu keinem Abverkauf im Handelsverlauf in USA kommt....bin ich seehr zuversichtlich das wir einer stabilen Trendwende entgegen sehen dürfen bei GALE.
Ich hoffe das die 2$ Marke bald.....gerissen werden wird !
Antwort auf Beitrag Nr.: 52.435.692 von Blackwater01 am 19.05.16 07:33:17@Blackwater, klasse Seite (die Chartdarstellung gefällt mir außerordentlich gut), Danke fürs reinstellen-Wilkommen im Bord, und am Board
Guten Morgen in die Runde!
Gale hat deren Ovarian Cancer Solution (301) gesternabend auf der ASCO convention vorgestellt, tja, wenn man die anschließende Kursverlauf etwas näher betrachtet, dann könnte man annehmen dass der Vortrag einige Teilnehmern wohl sehr gut gefallen hat
Galena Biopharma (GALE) to Present the GALE-301 Phase 1/2a Primary Analysis at ASCO
http://www.streetinsider.com/Corporate+News//Galena+Biopharm…
Ein paar interessanter statistiken im Bereich Gynecologic Cancer aus dem Beitrag anbei....
About Ovarian/Endometrial Cancers
New cases of ovarian cancer occur at an annual rate of 12.1 per 100,000 women in the U.S., with an estimated 21,290 cases for 2015. Although ovarian cancer represents about 1.3% of all cancers, it represents about 2.4% of all cancer deaths, or an estimated 14,180 deaths in 2015. Approximately 1.3% of women will be diagnosed with ovarian cancer at some point during their lifetime (2010 – 2012 data). The prevalence of ovarian cancer in the U.S. is about 192,000 women, and the five-year survivorship for women with ovarian cancer is 45.6%.
Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease, with an estimated 75% of women presenting with advanced-stage (III or IV) disease. These patients have their tumors routinely surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While many patients respond to this treatment regimen and become clinically free-of-disease, the majority of these patients will relapse. Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy ranges from 60% to 85%. Unfortunately for these women, once the disease recurs, treatment options are limited and the disease remains incurable.
New cases of endometrial cancer occur at an annual rate of 25.1 per 100,000 women in the U.S., with an estimated 54,870 cases for 2015. Although endometrial cancer represents about 3.3% of all cancers, it represents about 1.7% of all cancer deaths, or an estimated 10,170 deaths in 2015. Approximately 2.8% of women will be diagnosed with endometrial cancer at some point during their lifetime (2010 – 2012 data). The prevalence of endometrial cancer in the U.S. is about 620,000 women, and the five-year survivorship for women with endometrial cancer is 81.7%.
Gale hat deren Ovarian Cancer Solution (301) gesternabend auf der ASCO convention vorgestellt, tja, wenn man die anschließende Kursverlauf etwas näher betrachtet, dann könnte man annehmen dass der Vortrag einige Teilnehmern wohl sehr gut gefallen hat
Galena Biopharma (GALE) to Present the GALE-301 Phase 1/2a Primary Analysis at ASCO
http://www.streetinsider.com/Corporate+News//Galena+Biopharm…
Ein paar interessanter statistiken im Bereich Gynecologic Cancer aus dem Beitrag anbei....
About Ovarian/Endometrial Cancers
New cases of ovarian cancer occur at an annual rate of 12.1 per 100,000 women in the U.S., with an estimated 21,290 cases for 2015. Although ovarian cancer represents about 1.3% of all cancers, it represents about 2.4% of all cancer deaths, or an estimated 14,180 deaths in 2015. Approximately 1.3% of women will be diagnosed with ovarian cancer at some point during their lifetime (2010 – 2012 data). The prevalence of ovarian cancer in the U.S. is about 192,000 women, and the five-year survivorship for women with ovarian cancer is 45.6%.
Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease, with an estimated 75% of women presenting with advanced-stage (III or IV) disease. These patients have their tumors routinely surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While many patients respond to this treatment regimen and become clinically free-of-disease, the majority of these patients will relapse. Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy ranges from 60% to 85%. Unfortunately for these women, once the disease recurs, treatment options are limited and the disease remains incurable.
New cases of endometrial cancer occur at an annual rate of 25.1 per 100,000 women in the U.S., with an estimated 54,870 cases for 2015. Although endometrial cancer represents about 3.3% of all cancers, it represents about 1.7% of all cancer deaths, or an estimated 10,170 deaths in 2015. Approximately 2.8% of women will be diagnosed with endometrial cancer at some point during their lifetime (2010 – 2012 data). The prevalence of endometrial cancer in the U.S. is about 620,000 women, and the five-year survivorship for women with endometrial cancer is 81.7%.
Durchsuchen
